Inotiv (NASDAQ:NOTV) Announces Earnings Results, Misses Expectations By $0.10 EPS

Inotiv (NASDAQ:NOTV) announced its quarterly earnings results on Wednesday. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10), Zacks reports. Inotiv had a negative return on equity of 15.86% and a negative net margin of 22.10%.

Inotiv Stock Performance

NOTV traded down $0.13 during midday trading on Thursday, reaching $4.05. The company’s stock had a trading volume of 1,194,412 shares, compared to its average volume of 642,382. Inotiv has a twelve month low of $1.23 and a twelve month high of $11.42. The company has a fifty day simple moving average of $4.43 and a 200 day simple moving average of $2.80. The stock has a market cap of $105.34 million, a P/E ratio of -0.97 and a beta of 3.58. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 2.29.

Insider Transactions at Inotiv

In other news, Director Nigel Brown acquired 7,500 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of $4.26 per share, for a total transaction of $31,950.00. Following the transaction, the director now owns 65,537 shares of the company’s stock, valued at approximately $279,187.62. This represents a 12.92 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David Landman acquired 23,529 shares of Inotiv stock in a transaction on Thursday, December 19th. The stock was acquired at an average cost of $4.25 per share, for a total transaction of $99,998.25. Following the completion of the purchase, the director now owns 176,851 shares of the company’s stock, valued at approximately $751,616.75. The trade was a 15.35 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 71,029 shares of company stock worth $314,248 and have sold 26,872 shares worth $112,854. Insiders own 7.80% of the company’s stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.